Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome.
From 1st June 1989 to 31st May 1991, 78 women with a serum oestradiol level greater than 3500 pg/ml on the day of the ovulatory trigger, following pituitary suppression with buserelin and ovarian stimulation with human menopausal gonadotrophins (HMG), had all their embryos electively cryopreserved at the pronucleate stage to minimize the risk of developing ovarian hyperstimulation syndrome (OHS). Treatment with buserelin was continued in the luteal phase. A median of 19 oocytes (range 7-43) was obtained and 12 embryos (range 1-37) frozen per cycle. Twenty-one (27%) women developed OHS (six severe). Women developing OHS had higher (P less than 0.05) serum oestradiol concentrations on the 7th day after oocyte retrieval, compared to those who did not. No differences were found for any of the following criteria: aetiology of infertility, age, total dose of HMG, number of oocytes, fertilization rate or freeze-thaw survival of embryos. Subsequently, 125 frozen-thawed embryo replacements have been undertaken, using buserelin and hormone replacement therapy (HRT) (n = 93) or natural cycles (n = 32). The overall freeze-thaw survival and implantation rates per embryo were 71.8 and 11.7%, respectively. The pregnancy rates in natural cycles (19%) and buserelin/HRT cycles (29%) were not significantly different.
Wada
I
I
Manchester Fertility Services, BUPA Hospital, UK.
Matson
P L
PL
Troup
S A
SA
Hughes
S
S
Buck
P
P
Lieberman
B A
BA
D002064:Buserelin / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D015925:Cryopreservation; D010064:Embryo Implantation / Q000502:physiology*; D004622:Embryo, Mammalian; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D009865:Oocytes / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome / Q000175:diagnosis / Q000628:therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D011374:Progesterone; D004958:Estradiol; D002064:Buserelin